Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Philip L. Tzou"'
Autor:
Kaiming Tao, Zachary A. Osman, Philip L. Tzou, Soo-Yon Rhee, Vineet Ahluwalia, Robert W. Shafer
Publikováno v:
BMC Medical Research Methodology, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Large language models (LLMs) that can efficiently screen and identify studies meeting specific criteria would streamline literature reviews. Additionally, those capable of extracting data from publications would enhance knowledge
Externí odkaz:
https://doaj.org/article/644a26d55740400eb9522b8dba4a1b4f
Autor:
Kaiming Tao, Philip L. Tzou, Sergei L. Kosakovsky Pond, John P. A. Ioannidis, Robert W. Shafer
Publikováno v:
Microbiology Spectrum, Vol 10, Iss 4 (2022)
ABSTRACT SARS-CoV-2 Omicron variants contain many mutations in its spike receptor-binding domain, the target of all authorized monoclonal antibodies (MAbs). Determining the extent to which Omicron variants reduced MAb susceptibility is critical to pr
Externí odkaz:
https://doaj.org/article/b8a461e8a712480b863faa163a6ba332
Autor:
Kaiming Tao, Soo-Yon Rhee, Philip L. Tzou, Zachary A. Osman, Sergei L. Kosakovsky Pond, Susan P. Holmes, Robert W. Shafer
Publikováno v:
Viruses, Vol 15, Iss 4, p 992 (2023)
Background: With the approval of the HIV-1 capsid inhibitor, lenacapavir, capsid sequencing will be required for managing lenacapavir-experienced individuals with detectable viremia. Successful sequence interpretation will require examining new capsi
Externí odkaz:
https://doaj.org/article/660e68dcdb55445589d9c342138cbab0
Publikováno v:
PLoS ONE, Vol 17, Iss 3 (2022)
As novel SARS-CoV-2 variants with different patterns of spike protein mutations have emerged, the susceptibility of these variants to neutralization by antibodies has been rapidly assessed. However, neutralization data are generated using different a
Externí odkaz:
https://doaj.org/article/ddf5e532fa714ed4adb16464cf532ea9
Publikováno v:
Viruses, Vol 13, Iss 5, p 879 (2021)
In 2009, a list of nonpolymorphic HIV-1 drug resistance mutations (DRMs), called surveillance DRMs (SDRMs), was created to monitor transmitted drug resistance (TDR). Since 2009, TDR increased and antiretroviral therapy (ART) practices changed. We exa
Externí odkaz:
https://doaj.org/article/18dac1646eb84ded801d4bc33815e697
Autor:
Philip L. Tzou, Kaiming Tao, Janin Nouhin, Soo-Yon Rhee, Benjamin D. Hu, Shruti Pai, Neil Parkin, Robert W. Shafer
Publikováno v:
Viruses, Vol 12, Iss 9, p 1006 (2020)
Background: To prioritize the development of antiviral compounds, it is necessary to compare their relative preclinical activity and clinical efficacy. Methods: We reviewed in vitro, animal model, and clinical studies of candidate anti-coronavirus co
Externí odkaz:
https://doaj.org/article/7f9241b7d0da4a85a77da712dd18d165
Publikováno v:
AIDS Research and Human Retroviruses. 39:119-123
HIV-1 pol nucleotide ambiguities encoding amino acid mixtures occur commonly during population-based genotypic drug resistance testing. However, few studies have addressed the validity of sequences with fully ambiguous codons (FACs) containing codons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d451179fbe3b1dc1d08e0456c26a2535
https://doi.org/10.1089/aid.2022.0094
https://doi.org/10.1089/aid.2022.0094
Autor:
Geoffrey S. Gottlieb, Charlotte Charpentier, Susan Holmes, Vicente Soriano, Robert W. Shafer, Philip L Tzou, Soo-Yon Rhee, Robert A. Smith, Nuno Taveira, Carmen de Mendoza, Dana N. Raugi, Diane Descamps
Publikováno v:
J Infect Dis
BackgroundHIV-1 and HIV-2 differ in their antiretroviral (ARV) susceptibilities and drug resistance mutations (DRMs).MethodsWe analyzed published HIV-2 pol sequences to identify HIV-2 treatment-selected mutations (TSMs). Mutation prevalences were det
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff1e2e20c3a48d20e453949db6c3e7d
https://doi.org/10.1093/infdis/jiaa026
https://doi.org/10.1093/infdis/jiaa026
Autor:
Kaiming Tao, Robert W. Shafer, Janin Nouhin, Prasanna Jagannathan, Hector Bonilla, Philip L Tzou
Publikováno v:
Clinical Microbiology Reviews
SUMMARY The development of effective antiviral therapy for COVID-19 is critical for those awaiting vaccination, as well as for those who do not respond robustly to vaccination. This review summarizes 1 year of progress in the race to develop antivira
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a3b00141ff59eb089bd110d18087317
https://doi.org/10.1128/cmr.00109-21
https://doi.org/10.1128/cmr.00109-21
Autor:
Philip L. Tzou, Kaiming Tao, Malaya K. Sahoo, Sergei L. Kosakovsky Pond, Benjamin A. Pinsky, Robert W. Shafer
Publikováno v:
Journal of Clinical Virology. 157:105323
Although most laboratories are capable of employing established protocols to perform full-genome SARS-CoV-2 sequencing, many are unable to assess sequence quality, select appropriate mutation-detection thresholds, or report on the potential clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::734330950a666b1cd237ca6b33a95974
https://doi.org/10.1016/j.jcv.2022.105323
https://doi.org/10.1016/j.jcv.2022.105323